A neonatal thrombosis patient treated successfully with recombinant tissue plasminogen activator

Rekombinan doku plazminojen aktivatörü ile başarılı bir şekilde tedavi edilmiş bir neonatal tromboz olgusu

Kemal Erdinç¹, Serdar Ümit Sancı², Orçun Dabak¹, Orhan Gürsel³, Adem Güler⁴, Ahmet Emin Kürekçi³, Fuat Emre Canpolat²

¹Department of Pediatrics, Gülhane Military Medical Academy, Ankara, Turkey
²Department of Pediatrics, Division of Neonatology, Gülhane Military Medical Academy, Ankara, Turkey
³Department of Pediatrics, Division of Hematology, Gülhane Military Medical Academy, Ankara, Turkey
⁴Department of Cardiovascular Surgery, Gülhane Military Medical Academy, Ankara, Turkey

Abstract

Herein we report an asphyctic preterm neonate with respiratory distress and prothrombotic risk factors that responded positively to rtPA treatment following 2 attacks of acute thrombosis.

(Turk J Hematol doi:10.5152/tjh.2012.01)

Key words: Thrombosis, neonate, tissue plasminogen activator, preterm

Received: September 25, 2010  Accepted: March 05, 2011 Available Online Date: January 05, 2012

Özet

Bu yazıda solunum sıkıntısı ve asfiksi ile doğmuş, protrombotik risk faktörleri de olan bir prematüre bebekte iki tromboz atağının rekombinan doku plazminojen aktivatörü ile başarılı bir şekilde tedavi edilmesi sunulmuş, ilacın etkinliği ve bu grup hastalarda dahi uygulanabilirliği vurgulanmıştır.

(Turk J Hematol doi:10.5152/tjh.2012.01)

Anahtar kelimeler: Tromboz, yenidoğan, doku plazminojen aktivatörü, prematüre


Address for Correspondence: Dr. Kemal Erdinç, Department of Pediatrics, Gülhane Military Medical Academy, Ankara, Turkey Phone: +90 312 304 43 88 E-mail: kemalerdinc2005@yahoo.com
doi:10.5152/tjh.2012.01
Introduction

Thrombolytic treatment has increased in importance in recent years due to a significant increase in the number of neonatal cases diagnosed with thrombosis as a result of diagnostic and therapeutic interventions performed during the neonatal period [1]. Thrombolytic treatment is an alternative treatment for the elimination of thrombi, which may cause life-threatening organ and tissue destruction. Recombinant tissue plasminogen activator (rtPA), which is commonly used for the treatment of myocardial infarction and stroke in adults, has also been used to treat cardiac thrombi in patients with congenital heart disease and right-to-left shunting [2-4]. Research on the use of rtPA in neonates is limited [5]. Herein we report an asphyctic preterm neonate with respiratory distress and prothrombotic risk factors that responded positively to rtPA treatment following 2 attacks of acute thrombosis.

Case Report

A preterm male neonate weighing 940 g that was born to a 25-year-old gravida 8, para 2 mother was transferred 3 h after birth due to respiratory distress from another hospital to our neonatal intensive care unit in an intubated and hand (bag)-ventilated manner in a transport incubator. The mother had not menstruated during the previous 2 years and, therefore, the neonate’s gestational age was estimated to be 27 weeks based on the Ballard score. The mother’s obstetric history included 5 abortions and 2 curettages, and an emergency cesarean section due to placenta previa the day she presented with vaginal bleeding to a hospital in a neighboring town.

Physical examination of the neonate showed hypothermia, hypotonia, cyanosis, intercostal and subcostal retractions, grunting, and tachypnea. The patient was diagnosed as hyaline membrane disease, and mechanical ventilation with intratracheal surfactant treatment, parenteral fluid, and empirical antibiotic treatment were initiated. Coldness, pallor, and cyanosis developed in the distal region of the left foot, and coldness, pallor, and cyanosis developed in the 1st, 2nd, and 4th phalanges of the left foot. Blood was withdrawn to analyze the coagulation profile, and heparin treatment with a 100 U kg⁻¹ loading dose and 25 U kg⁻¹ maintenance dose, and intravenous alteplase infusion (0.2 mg kg⁻¹ h⁻¹) were initiated and administered for 8 h. Fresh frozen plasma infusion (10 mL kg⁻¹ b.i.d.) was also initiated. This treatment regimen resulted in complete recovery in 48 h.

Etiologic investigation of the recurring thrombus formation showed that the neonate had a heterozygous factor V Leiden mutation, a homozygous plasminogen activator inhibitor-1 (PAI-1) 5G/5G mutation, a heterozygous methyl tetrahydrofolate reductase (MTHFR) mutation, and a normal prothrombin 20210A gene structure. Maintenance treatment with subcutaneous low-molecular weight heparin (enoxaparin) (0.2 mg kg⁻¹ b.i.d.) was initiated and a therapeutic anti-factor Xa level of 0.5-1 U mL⁻¹ was targeted. At the time this report was written, the patient was being followed-up as an outpatient with the diagnosis of chronic lung disease of prematurity.

Discussion

The incidence of symptomatic neonatal thrombosis, including that in the central nervous system, is reported to be 0.51 per 10,000 live births [1]. Along with advancements in diagnosis and treatment, and because of various invasive interventions performed in neonates, the annual incidence may increase to 2.4 per 1000 in neonatal intensive care units [6].
Thrombi may occur at arterial catheter entry regions and in the presence of prothrombotic risk factors, such as factor V Leiden mutation, and deficiencies in protein C and protein S.

There is no consensus concerning the optimal mode of treatment for thrombosis, especially in neonates. Thrombolytic treatment is being used with increasing frequency for thrombi in neonates. Thrombolytic treatment is an alternative treatment for the elimination of thrombi, which can cause life-threatening organ and tissue destruction [7].

A study that included 14 neonates with a diagnosis of thrombosis treated with rtPA reported that it was a safe treatment option [8]. rtPA has been effectively used to treat catheter-related intracardiac thrombus and vena cava inferior thrombus [9,10]. A study that included 20 children (aged between 1 day and 16 years) with thrombosis reported that 11 patients treated with rtPA had a complete response [11]. In the presented case, the mother’s history of recurrent abortus, hematochezia during the first hours of life, and development of an acute thrombus in the region of the brachial artery suggested that the patient had an underlying prothrombotic disease. In addition to this clinical finding as the patient was born preterm (estimated gestational age: 27 weeks) and had respiratory distress syndrome we chose to treat the infant with rtPA in accordance with a previous report of a patient with a brachial artery thrombus that was successfully treated with rtPA [12].

rtPA is characterized by a locally potent effect, which helps minimize the occurrence of systemic side effects. rtPA has a rapid curative effect on thrombi, which is a great benefit as it can minimize the incidence of acute tissue and organ necrosis. In the presented case a rapid response to the patient's second attack of thrombus (lower extremity), complete recovery was achieved, indicating that the combination of these 2 drugs is safe for the treatment of recurrent thrombi. The combination of heparin and thrombolytic treatment has previously been reported to be safe and effective [13]. Although data about the use of this drug combination in neonates, especially preterm neonates, are limited, it is an alternative choice of treatment in cases of life-threatening illness and for preventing acute necrosis in extremities due to thrombus [5]. The presented case had a complete response without any tissue loss, following rapid diagnosis and treatment. The literature contains few reports on the use of rtPA in preterm neonates, and fewer cases with birth weights <1000 g, as was the presented case [14]. The presented case shows that use of rtPA in preterm neonates, even repeated doses, can be safe and effective; however, larger prospective, controlled clinical trials are needed to more fully demonstrate the safety and effectiveness of rtPA in neonates.

Acknowledgment

We are grateful to Nejat Akar, MD and Yonca Eğin, PhD of Ankara University, School of Medicine, Department of Molecular Hematology.

Conflict of interest statement

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References


